Apixan
Generic Name
Apixaban
Manufacturer
Beximco Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| apixan 5 mg tablet | ৳ 20.00 | ৳ 200.00 |
Description
Overview of the medicine
Apixan 5 mg Tablet contains Apixaban, an oral anticoagulant used to prevent and treat blood clots. It is a direct factor Xa inhibitor, which plays a critical role in the blood clotting cascade. This medicine is prescribed for conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism.
Uses & Indications
Dosage
Adults
Nonvalvular Atrial Fibrillation: 5 mg orally twice daily. For patients with at least two of the following characteristics (age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dL), the recommended dose is 2.5 mg orally twice daily. Treatment of DVT/PE: 10 mg orally twice daily for 7 days, followed by 5 mg orally twice daily.
Elderly
No general dose adjustment is required based on age alone. However, dose reduction to 2.5 mg twice daily may be considered for NVAF patients with specific criteria (age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dL).
Renal_impairment
For NVAF patients with severe renal impairment (creatinine clearance 15-29 mL/min) or on dialysis, the recommended dose is 2.5 mg orally twice daily. For DVT/PE treatment, no dose adjustment for mild to moderate impairment; for severe impairment, caution is advised, and alternative anticoagulation may be considered.
How to Take
Take Apixan 5 mg Tablet orally with or without food, as directed by your physician. Swallow the tablet whole with water. Do not crush or chew the tablet.
Mechanism of Action
Apixaban is a selective, reversible, direct inhibitor of Factor Xa. By inhibiting Factor Xa, apixaban prevents thrombin generation and thrombus (blood clot) formation. This interrupts the intrinsic and extrinsic pathways of the blood coagulation cascade, thereby reducing the risk of blood clots.
Pharmacokinetics
Onset
Anticoagulant effect observed within a few hours of administration.
Excretion
Approximately 27% excreted renally as unchanged drug, and the remainder is excreted via biliary-faecal route.
Half life
Approximately 12 hours.
Absorption
Rapidly absorbed, with peak plasma concentrations occurring 3-4 hours after oral administration. Absolute bioavailability is approximately 50% for 10 mg oral dose.
Metabolism
Primarily metabolized via CYP3A4/5, with minor contributions from CYP1A2, 2C8, 2C9, 2C19, and 2J2. Approximately 25% of the dose is metabolized.
Side Effects
Contraindications
- •Active pathological bleeding (e.g., gastrointestinal bleeding, intracranial hemorrhage)
- •Known severe hypersensitivity to apixaban or any component of the product
Drug Interactions
Antiplatelet agents (e.g., aspirin, clopidogrel, NSAIDs)
Increased risk of bleeding. Use with caution, especially in patients at high risk of bleeding.
Other anticoagulants (e.g., warfarin, heparin, dabigatran, rivaroxaban)
Increased risk of bleeding. Avoid concomitant use unless benefits outweigh risks and close monitoring is possible.
Strong dual inducers of CYP3A4 and P-gp (e.g., rifampin, phenytoin, carbamazepine, St. John's Wort)
Decrease apixaban exposure and may reduce efficacy. Avoid co-administration.
Strong dual inhibitors of CYP3A4 and P-gp (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir)
Increase apixaban exposure and bleeding risk. Reduce apixaban dose to 2.5 mg twice daily for NVAF patients.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Overdose of apixaban increases the risk of bleeding. There is no specific antidote for apixaban that reverses its anticoagulant effect directly, but a reversal agent (andexanet alfa) is available for life-threatening bleeding. Symptomatic treatment and appropriate supportive care should be instituted.
Pregnancy & Lactation
Pregnancy Category B. There are no adequate and well-controlled studies of apixaban in pregnant women. Apixan should be used during pregnancy only if the potential benefit justifies the potential risk to the mother and fetus. It is not known whether apixaban or its metabolites are excreted in human milk; therefore, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from the date of manufacture, specific expiry date mentioned on the pack.
Availability
Available in pharmacies and hospitals
Approval Status
Approved by FDA and DGDA
Patent Status
Generic available; patent expired in most regions for active ingredient
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
